Allogene Therapeutics (ALLO) Income from Continuing Operations (2018 - 2026)
Allogene Therapeutics (ALLO) reported Income from Continuing Operations of 145209000.0 for Q1 2026, down 96.88% on a YoY basis from 4658436096.56 in Q1 2025, and down 271.79% sequentially from 39057000.0 in Q4 2025.
Allogene Therapeutics (ALLO) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Allogene Therapeutics (ALLO) has 9 years of Income from Continuing Operations data on file, last reported at 145209000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 96.88% year-over-year to 145209000.0; the trailing twelve-month figure through Mar 2026 stood at 325834000.0 (up 18.94% YoY), and the FY2025 full-year result was 190886000.0, up 25.9% from the prior year.
- Income from Continuing Operations slipped to 145209000.0 in Q1 2026, from 39057000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 39057000.0 in Q4 2025 to a low of 224928000.0 in Q3 2022.
- A 5-year average of 99940941.18 and a median of 81522000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 1436157.14% in 2022 and jumped 60.27% in 2025, its largest moves.
- Tracing ALLO's Income from Continuing Operations over 5 years: stood at 100538000.0 in 2022, then climbed by 27.55% to 72844000.0 in 2023, then advanced by 21.0% to 57544000.0 in 2024, then jumped by 32.13% to 39057000.0 in 2025, then sank by 271.79% to 145209000.0 in 2026.
- Business Quant data shows ALLO's Income from Continuing Operations at 145209000.0 in Q1 2026, 39057000.0 in Q4 2025, and 65286000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Allogene Therapeutics | 421.71 Mn | 421.71 Mn | - | -145.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.21 Mn |
| Dec 31, 2025 | -39.06 Mn |
| Sep 30, 2025 | -65.29 Mn |
| Jun 30, 2025 | -76.28 Mn |
| Mar 31, 2025 | -73.75 Mn |
| Dec 31, 2024 | -57.54 Mn |
| Sep 30, 2024 | -78.68 Mn |
| Jun 30, 2024 | -191.98 Mn |
| Mar 31, 2024 | -77.68 Mn |
| Dec 31, 2023 | -72.84 Mn |
| Sep 30, 2023 | -91.53 Mn |
| Jun 30, 2023 | -113.01 Mn |
| Mar 31, 2023 | -100.03 Mn |
| Dec 31, 2022 | -100.54 Mn |
| Sep 30, 2022 | -224.93 Mn |
| Jun 30, 2022 | -109.12 Mn |
| Mar 31, 2022 | -81.52 Mn |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | -160.39 Mn |
| Jun 30, 2021 | -146.94 Mn |